Alternative Pharmacologic Strategies to Ivabradine for Tachycardia Management

Acute Rate‑Control Options

Beta‑blockers are the primary acute alternatives for hemodynamically stable supraventricular tachycardia; metoprolol 2.5–5 mg IV over 2 min (up to three doses), esmolol 500 µg/kg IV bolus then 50–300 µg/kg/min infusion, and propranolol 1 mg IV over 1 min (repeat up to three doses) are recommended. [@1]
Non‑dihydropyridine calcium‑channel blockers (CCBs) are equally effective acute alternatives; diltiazem 0.25 mg/kg IV bolus (15–20 mg) with possible repeat 20–25 mg after 15 min and infusion 5–15 mg/h, and verapamil 5–10 mg IV bolus (repeat 10 mg after 30 min) with infusion 0.005 mg/kg/min can be used. [@1, @3]
2020 ESC guidelines upgraded beta‑blockers and downgraded diltiazem and verapamil for acute narrow‑QRS tachycardias, reflecting a shift toward beta‑blocker preference. [@4, @5]

AV‑nodal blocking agents (beta‑blockers, CCBs, digoxin, adenosine) must be avoided in pre‑excited atrial fibrillation/flutter with accessory‑pathway conduction because they may accelerate ventricular response. [@1, @3]
Calcium‑channel blockers should not be used in decompensated heart failure with reduced ejection fraction; beta‑blockers are preferred in this population. [@1, @2]
Beta‑blockers require caution in patients with obstructive pulmonary disease or reactive airway disease. [@1, @3]
CCBs need dose adjustment in hepatic or renal impairment. [@1]
Digoxin dosing must be guided by renal function and serum levels; target concentrations <0.8 ng/mL to avoid toxicity. [@10]

Beta‑blockers, diltiazem, and verapamil remain the standard agents for long‑term rate control in atrial flutter and atrial fibrillation. [@2, @6]
Oral metoprolol is typically titrated to 25–100 mg twice daily or 50–400 mg daily extended‑release. [@7]
Oral diltiazem is usually given 120–360 mg daily extended‑release. [@7]
Oral verapamil is usually given 180–480 mg daily extended‑release. [@7]
Digoxin is an alternative for patients with heart failure or left‑ventricular dysfunction, but it is less effective during exercise or high sympathetic tone and has a delayed onset (60 min–6 h). [@1, @8]
2020 ESC guidelines no longer recommend digoxin for acute narrow‑QRS tachycardias. [@4, @5]
Amiodarone is reserved for refractory cases; it can be useful for acute rate control in atrial flutter with systolic heart failure when beta‑blockers are contraindicated, but it is not recommended for long‑term rate control due to toxicity. [@6, @2, @9]

When monotherapy fails, combining digoxin with a beta‑blocker provides synergistic AV‑nodal blockade and is more effective than digoxin plus a CCB. [@8]
Careful heart‑rate monitoring is required when combining AV‑nodal blocking agents to avoid excessive bradycardia. [@8]

Inappropriate Sinus Tachycardia (IST): beta‑blockers are the primary alternative to ivabradine; verapamil and diltiazem are no longer recommended per 2020 ESC guidelines. [@4, @5]
2020 ESC guidelines list ivabradine (alone or with beta‑blockers) as a therapeutic option for symptomatic IST, although this indication is not EMA‑approved. [@4, @5]
Atrial Flutter – Rhythm Control:
- Dofetilide or ibutilide are effective for acute pharmacologic cardioversion. [@2, @9]
- Catheter ablation of the cavotricuspid isthmus is preferred over long‑term drug therapy for symptomatic or refractory cases. [@2, @9, @6]
Atrial Flutter – Maintenance of Sinus Rhythm (when ablation is not pursued): amiodarone, dofetilide, or sotalol may be used depending on underlying heart disease. [@9]

Normal or preserved function – beta‑blockers are now preferred (per 2020 ESC), with CCBs as alternatives. [@4, @5]
Reduced ejection fraction/heart failure – beta‑blockers first‑line; digoxin or amiodarone as alternatives. [@2, @6]
Bronchospasm/COPD – prefer CCBs over beta‑blockers. [@8]
Renal dysfunction – adjust or avoid digoxin; select alternative agents. [@1]